



Economic and Social Council

Distr.: General
3 November 2014

Original: English

2014 session

Item 4 of the provisional agenda*

Elections, nominations, confirmations and appointments

Election of one member of the International Narcotics Control Board from among candidates nominated by the World Health Organization

Note by the Secretary-General

1. The present note contains information on candidates nominated by the World Health Organization (WHO).
2. In accordance with established procedure, the Secretary-General invited the Director-General of WHO to submit a list of candidates for election to membership in the International Narcotics Control Board for the period from 2 March 2015 to 1 March 2020 on the expiration of the term of office of one member of the Board who was originally nominated by WHO and elected by the Economic and Social Council in 2009. The post is currently occupied by Rajat Ray (India).
3. The Economic and Social Council, in its decision 2014/201 A of 23 April 2014, decided to reverse the sequence of election of members of the Board for the election in 2014 so that the election of five members from among candidates nominated by Governments would be held first. The Council also decided to postpone the election of one member of the Board from among candidates nominated by WHO in order to enable WHO to review its list of candidates. Furthermore, in a note dated 12 May 2014, the Secretary-General invited the Director-General of WHO, if deemed appropriate, to submit a revised list of candidates.
4. As at 31 October 2014, four candidates had been proposed by WHO. Their names are given below in alphabetical order:

Hao Wei China
Jaanus Harro Estonia
Baba Koumare Mali
Emilis Subata Lithuania

* E/2014/1/Rev.1, annex II.



5. The biographical information that was transmitted with the proposals for candidatures is contained in the annex to the present note.

6. In accordance with article 9, paragraph 2, of the Single Convention on Narcotic Drugs, 1961,¹ as amended by the 1972 Protocol,² members of the Board shall not hold positions or engage in any activity that would be liable to impair their impartiality in the exercise of their functions. Positions and activities of individuals in the following areas are, in particular, incompatible with membership of the Board: persons who hold government posts, are in the paid service of their Governments or are acting under instructions from their Governments; persons who represent a Government at national or international forums on drug-related issues; and persons who are engaged in any activity, whether private or public, that might be liable to impair their impartiality in the exercise of their functions on the Board or whose activity is in conflict with the functions of the Board.

7. Document E/2014/9/Add.7 contains information on the number, length and place of meetings of the Board in 2013, on payments to members and on present membership (annex I); articles 9 (Composition and functions of the Board) and 10 (Terms of office and remuneration of members of the Board) of the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol (annex II); information on qualifications and other conditions of membership on the Board (annex III); and a list of the States parties to the Single Convention of 1961 and that Convention as amended by the 1972 Protocol, the Convention on Psychotropic Substances of 1971³ and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988⁴ (annex IV).

¹ United Nations, *Treaty Series*, vol. 520, No. 7515.

² *Ibid.*, vol. 976, No. 14151.

³ *Ibid.*, vol. 1019, No. 14956.

⁴ United Nations publication, Sales No. E.91.XI.6.

Annex

Biographical information on candidates for election to the International Narcotics Control Board*

1. Hao Wei (China)

Education

Doctor (Ph.D.), Psychiatry, Hamamatsu Medical University; MSc Psychiatry, Hunan Medical University; BSc Clinical Medicine, Faculty of Clinical Medicine, Anhui Medical University.

Present posts

Professor of Psychiatry. Deputy Director of Mental Health Institute, Central South University and Director of WHO Collaborating Centre for Psychosocial Factors, Substance Abuse and Health (WPRO).

Previous posts

Scientist, Substance Abuse Department, WHO headquarters (1999-2000); Medical Officer, Mental Health and Substance Abuse, WHO/WPRO (2003-2004).

Memberships

President, Chinese Psychiatrist Association (2008-2011); President, Chinese Association of Addictive Medicine (2014); Vice-President, Chinese Drug Abuse Treatment and Prevention Association (Since 2010); Member, Scientific Advisory Committee on Tobacco Product Regulation, WHO (2000-2004); Member, WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems (since 2006); National Focal Point for China for the implementation of the Regional Plan of Action for the Reduction of alcohol-related harm in the Western Pacific, WHO (since 2009); Chair, Education Committee of the Asian-Pacific Society for Alcohol and Addiction Research (since 2009).

Selected publications

Publications in peer-reviewed journals: Hao W., Young D.S. and Li L.J. (1995), "Psychoactive substance use in China: Gender differences and related factors", *Addiction*, 90:1505-1517; Hao W. (1995), "Commentary: Alcohol use and public good, a Chinese view", *Addiction*, 90:1448-1450; Hao W., Young D. (1999), "Alcohol consumption and alcohol-related problems: Chinese experience from six area samples, 1998", *Addiction* 94:1567-1576; Hao W., Young D. (2000), "Drinking patterns and problems in China," invited review, *Journal of Substance Use*, 5:71-78; Hao W., Xiao S.Y., Liu T.Q., et al (2002), "The second National Epidemiological Survey on illicit drug use at six high-prevalence areas in China: prevalence rates and use patterns", *Addiction*, 97, 1305-1315; Cochrane J., Chen H.H., Conigrave K.M., and Hao W. (2003), "Alcohol use in China", invited review, *Alcohol and Alcoholism*, 38: 537-542; Hao H., Su Z.H., Xiao S.Y. et al (2004), "Longitudinal surveys of prevalence rates and use patterns of illicit drugs at selected high-prevalence areas in

* Curricula vitae are issued without formal editing.

China from 1993 to 2000”, *Addiction*, 99: 1176-1180; Hao W., Su Z.H., Liu B.L. et al., (2004), “Drinking and drinking patterns and health status in the general population of five areas of China”, *Alcohol and Alcoholism*, 39:43-52; Hao W., Chen H., Su Z.H. (2005), “National experiences: China, alcohol today”, *Addiction* 100:737-741; Zhou X.H., Su Z.H., Deng H.Q., Xiang X.J., Chen H.X., Hao W. (2006), “A comparative survey on alcohol and tobacco use in urban and rural populations in the Huaihua District of Hunan Province”, *China Alcohol*, 39:87-96 (English), corresponding author; Hao W., Tan L.X., Tang Q.S, Commentary on Klingemann et al. (2010): “Towards a self-change-friendly treatment and policy for addictive behaviour”, *Addiction*, 105:1519-1520, corresponding author; Deng Q.J., Tang Q.S., Schottenfeld, Hao W., Chawarski M., “Drug use in rural China: a preliminary investigation in Hunan Province, *Addiction*, in press, co-corresponding author; Wang X.Y., Yu R.J., Zhou X.H., Liao Y.H., Tang J.S., Liu T.Q., Shan B.C., Hao W., “Reversible brain white matter microstructure changes in heroin addicts: a longitudinal study”, *Addiction Biology*, published online, corresponding author; Zhou L., Zhang G.B., Hu H.X., Fan Z.J., Hao W., “Perceived interpersonal pressure and drinking behaviour in South China drug and alcohol dependence (2013), 130:122-128, corresponding author; Liu L., Luo T., Hao W., “Gambling problems in young people: experience from the Asian region” (2013), *Current Opinion in Psychiatry*, 26:310-317, corresponding author; Luo T., Wang J., Li Y.H., Wang X.Y., Tan L.X., Deng Q.J., Thakoor J., Hao W., “Stigmatization of people with drug dependence in China: a community-based study in Hunan province” (2013), *Drug Alcohol Dependence*.

2. Jaanus Harro (Estonia)

Education

Graduated (M.D.) from the Faculty of Medicine, University of Tartu, Estonia (1987); postgraduate studies in psychopharmacology at the Department of Pharmacology, University of Tartu (1987-1990); Ph.D. in pharmacology, University of Tartu (1990). Doctor of Medical Science, Uppsala University, Sweden (1993).

Present post

Professor of Psychophysiology, Department of Psychology, University of Tartu (since 1998).

Previous posts

Full Professor of Health Promotion (personal appointment), Estonian health project affiliated with the Department of Public Health, University of Tartu, Estonia (1996-1998); Vice-Dean, Preclinical Medicine, Faculty of Medicine, University of Tartu (1994-1998); Professor of Neuropsychopharmacology (personal appointment), Department of Pharmacology, University of Tartu (1994-1996); Senior Researcher in Neurobiology, Head, Psychopharmacology Unit, Department of Physiology, University of Tartu (1993); Acting Head of the Laboratory of Psychopharmacology, Institute of General and Molecular Pathology, University of Tartu (1993); Assistant Professor in Basic Pharmacology, University of Tartu (1989-1990); Staff Scientist at the Laboratory of Psychopharmacology, Institute of General and Molecular Pathology, University of Tartu (1989-1992); Research Associate at the Department of Pharmacology, University of Tartu (1987-1989).

Memberships

Collegium Internationale Neuro-Psychopharmacologicum (International College of Neuropsychopharmacology — CINP), Member of the Education Committee since June 2004; Society for Neuroscience; European College of Neuropsychopharmacology; International Society of Psychoneuroendocrinology; International Brain Research Organization; Estonian Society of Pharmacology; Estonian Union of Psychologists; Estonian Society of Psychiatrists; National Geographic Society; Foreign Member, the Royal Society of Sciences at Uppsala (Class for Natural History and Medicine) (2011).

Publications

More than 170 papers and chapters in internationally, broadly available journals and books, inter alia: *In the Age of Intoxicants*, ISBN 9949-11-214-1; 317 pages), Tartu University Press, 2006 (monograph, in Estonian); S. Oreland, K. Raudkivi, L. Oreland, J. Harro, L. Arborelius and I. Nylander, "Ethanol-induced effects on the dopamine and serotonin systems in adult Wistar rats are dependent on early-life experiences", *Brain Research* (2011) 1405, 57-68; L. Merenäkk, J. Mäestu, N. Nordquist, J. Parik, L. Oreland, H.-M. Loit and J. Harro, "Effects of the serotonin transporter (5-HTTLPR) and α 2A-adrenoceptor (C-1291G) genotypes on substance use in children and adolescents: a longitudinal study", *Psychopharmacology* (2011) 215, 13-22; J. Harro, "Inter-individual differences in neurobiology as vulnerability factors for affective disorders: implications for psychopharmacology", *Pharmacology and Therapeutics* (2010) 125, 402-422; A. L. Garcia-Garcia, N. Elizalde, D. Matrov, J. Harro,

S. M. Wojcik, E. Venzala, M. J. Ramirez, J. Del Rio and R. M. Tordera, "Increased vulnerability to depressive-like behaviour of mice with decreased expression of VGLUT1", *Biological Psychiatry* (2009) 66, 275-282; A. Alntoa, M. Eller, L. Herm, A. Rincken and J. Harro, "Amphetamine-induced locomotion, behavioural sensitization to amphetamine, and striatal D2 receptor function in rats with high or low spontaneous exploratory activity: differences in the role of locus coeruleus", *Brain Research* (2007) 1131, 138-148.

Honours

European College of Neuropsychopharmacology Fellowship Award (1993); CINP Ole Rafaelsen Fellowship Award (1998); Medal of the City of Tartu (2002); National Annual Prize in Medical Sciences (2005); Order of the White Star, Class IV (2006).

Meetings attended

Invited to speak at more than 30 international conferences, inter alia: EuroScience Open Forum, Dublin, 11-15 July 2012; Haifa Forum for Brain and Behaviour, Haifa, 5-7 February 2012; Conference of the International Society for the Study of Individual Differences, London, 25-28 July 2011; conferences and congresses of the European College of Neuropsychopharmacology.

3. Baba Koumare (Mali)

Education

Full Professor with accreditation in July 1993 by the Specialized Technical Committee (CTS) of the African and Malagasy Council for Higher Education (CAMES), Yaoundé (July 1999); Full Professor, Chair for Psychiatry and Medical Psychology, Bamako, Mali (July 1993); University Professor, Competitive Examination in Psychiatry, Paris, France (April 1986); Intern in neurology, Fann National University Hospital Centre (CHU Fann), Dakar, Senegal (1980-1981); Certificate of Specialist Training (CES) in Psychiatry, Dakar, Senegal (June 1980); Doctor of Medicine Degree, Dakar, Senegal (July 1978); Residency in Psychiatry at Dakar Hospitals, Senegal (December 1977); Baccalaureate Part II, Biological Sciences, (Series D), Bamako, Mali, Grade: cum laude (July 1969).

Present posts

Chief, Psychiatry Service, Hospital Point G, Bamako, Mali (1985-2014); Full University Professor and Hospital Physician, Senior Officer for the Teaching of Psychiatry and Psychology at the Faculty of Medicine, Pharmacy and Dentistry of Bamako, Mali (1982-2014); Member National Health Council (1993-2014).

Previous posts

Coordinator of the National Programme for Mental Health and the Fight against Drug Addiction (Ministry of Health, Social Cohesion and the Elderly) (1982-2014); Vice-President of the Hospital Medical Commission of Hospital Point G (1999-2002); Chief, Department of Medicinal and Specialized Medical Research of the Faculty of Medicine and Dentistry, Cheikh Anta Diop University, Dakar (1999-2006); Chief, Neuro-Psychiatry Service, Hospital Point G, Bamako, Mali (January 1983-December 1984); National Expert to the Mali Courts (1982-2014); Chief Physician, Mental Health Section (Ministry of Public Health and Social Affairs) (1982-1992).

Memberships

Member of the Dakar Psychopathology and Mental Health Society; Associate foreign member of the Medico-Psychological Society; Assistant Secretary-General of the Association of Psychiatrists in Africa; Corresponding member of the French-language Society of Medical Psychology; President of the Association of Psychiatrists of Sub-saharan Francophone Africa (1989-2011); Assistant Vice-President of the World Association for Psychosocial Rehabilitation (1989); Member of the Mali Society of Medicine; President of the Malian Association of Care for the Mentally Ill; Member of the Scientific Committee of the International Institute for Training and the Fight against Drugs; President of the Mali Action Group for Drug Abuse Monitoring and Control; President of the National Federation of Drug Control Associations and NGOs; President of the Subcommission for Prevention, Awareness-Raising and Training of the National Drug Control Commission.

Selected publications

“Santé Mentale au Mali” (Mental Health in Mali), under the guidance of Baba Koumaré; Avenues of theoretical exploration and research undertaken since 1982 by the psychiatric team at Bamako in collaboration with Canadian and Italian research scientists (McGill University, Montreal, and CNR, Pérouse) in various fields of clinical, therapeutic, epidemiological and anthropological research, *Psychopathologie Africaine*, 1992, Vol. XXIV, No. 2 (287 pages).

Selected meetings attended

Participation in expert meeting in conjunction with the sixth session of the African Union Conference of Ministers for Drug Control at Addis Ababa, Ethiopia (6-10 October 2014); Participation in the tenth meeting of the Inter-Ministerial Drug Coordinating Committee of the Economic Community of West African States (ECOWAS) members, held at Cotonou, Benin, organized by ECOWAS (January 2014); Participation in the meeting of drug experts organized by the African Union and ECOWAS at Kampala, Uganda (February 2013); Participation in the meeting of drug demand reduction experts, held at Mombasa, organized by the United Nations Office on Drugs and Crime (19-22 April 2006).

4. Emilis Subata (Lithuania)

Education

Faculty of Medicine, Vilnius University (M.D.) (1981); postgraduate studies in psychiatry, University of Tartu (1987-1990); Ph.D. in psychiatry, University of Tartu (1990).

Present posts

Director of Vilnius Centre for Addictive Disorders, physician psychiatrist (part-time); Associate Professor at Psychiatry Clinic of Vilnius University (since 1999) (part-time), Leader of post-graduate training courses for physicians, mentor of psychiatrists-residents of Vilnius University Psychiatry Clinic; Member of WHO Collaborating Centre for Harm Reduction at Vilnius University Public Health Institute (since 2013), representing Vilnius Centre for Addictive Disorders.

Previous posts

Head of Substance Abuse Research Unit, Institute of Hygiene of the Ministry of Health, Vilnius (1982-1991); Researcher, Tartu State University, Estonia (1989-1990); Technical Adviser, Open Society Institute (New York), International Harm Reduction Development Programme, Vilnius (1999-2005); Consultant, World Bank (2003); Principal Investigator, WHO Geneva, Vilnius (2003-2006); Technical Adviser, UNODC Moldova, Ukraine (2004-2005); Consultant, Central and Eastern European Harm Reduction Network, Vilnius (2005); Expert, Member of Technical Development Group, WHO Geneva, Department of Mental Health and Substance Abuse, Geneva, Vienna (2005-2007); Technical Assistant, WHO Regional Office for Europe, Tashkent, Uzbekistan (2005-2006).

Memberships

Member of the Executive Board of the International Harm Reduction Association (2004-2007); Member of the United Nations Reference Group on HIV Prevention and Care among injecting drug users (2003-2007); President of Lithuanian Psychiatric Association (2000-2005), Vice-President (2008-2011); Member of the Steering Committee of Central and Eastern European Harm Reduction Network (1977-2000), Coordinator (2000-2002); President of Lithuanian Association of Addiction Psychiatry (since 2007); Member of International Society of Addiction Medicine (since 2012).

Selected publications

Padaiga Ž., Subata E., Vanagas G., “Outpatient methadone maintenance treatment programme: Quality of life and health of opioid-dependent persons in Lithuania”, *Medicina*, 2007; 43(3). — 235-241; Subata E., “Methadone maintenance treatment of opioid dependence in Lithuania: Challenges, solutions and integration with HIV/AIDS treatment and care”, *Chinese Journal of Drug Dependence*, 2007/16/3, 174-178; Subata E., *Evaluation of methadone maintenance therapy programmes in Estonia*, 2007; Peter Lawrinson, Robert Ali, Aumphornpun Buavirat, Sithisat Chiamwongpaet, Sergey Dvoryak, Boguslaw Habrat, Shi Jie, Ratna Mardiati, Azaraksh Mokri, Jacek Moskalewicz, David Newcombe, Vladimir Poznyak, Emilis Subata, Ambrose Uchtenhagen, Diah S.Utami, Robyn Vial and Chengzheng Zhao,

“Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS”, *Addiction*, 2008, 103, 1484-1492; Subata E., Pincevičiute E., “Opioid dependence treatment with naltrexone, national clinical protocol (in Lithuanian)”, *Lithuanian Psychiatric Association*, 2008, p. 12; Michael Schaub, Emilis Subata, Victor Chtengelov, Gundo Weiler, Ambros Uchtenhagen, “Feasibility of Buprenorphine maintenance therapy programmes in Ukraine”, *European Addiction Research*, 2009,15: 157-162; Subata E., Karymbaeva S., Moller L., “Evaluation of opioid maintenance treatment in the Kyrgyz Republic”, WHO Regional Office for Europe, p.16; Moller L., Karymbaeva S., Subata E., Kiaer T. (2009), “Evaluation of patients in opioid substitution therapy in the Kyrgyz Republic,” WHO Regional Office for Europe; M. Schaub, V. Chtenguelov, E. Subata, G. Weiler, A. Uchtenhagen, “Feasibility of buprenorphine and methadone maintenance programmes among users of homemade opioids in Ukraine”, *International Journal of Drug Policy*, 2010, Volume 21, Issue 3, pp. 229-233; Subata E., Danileviciute V., Adomaitiene V., Matulionyte R., Naujokiene S., Malinauskaite A., “Opioid dependence treatment with Methadone”, national clinical protocol, Lithuanian Psychiatric Association, UNODC, 2010, p. 32; Subata E., Danileviciute V., Adomaitiene V., Matulionyte R., Kuznecova J., Sinkuniene N., Zamkovaja S., Zikaras T., Naujokiene S., Malinauskaite A., “Opioid dependence treatment with buprenorphine and buprenorphine/naltrexone, national clinical protocol, Lithuanian Psychiatric Association, 2010, p. 33; Addiction Severity Index, UNODC Treatnet, 5th edition, 3.0 version (Lithuanian translation), adapted by Subata E., Malinauskaite E., Pinceviciute E. and others, Vilnius Centre for Addictive Disorders, 2010, p. 12; Amass, L. Pukeleviciene, V. Subata. E. et al, “A prospective, randomized, multicentre acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals”, *Addiction*, 2010, Vol. 107 Issue: 1, pp. 142-151; Subata E., Karymbaeva S. Moller L., “Evaluation of opioid substitution therapy in prisons”, pilot study in Kyrgyzstan, WHO Regional Office for Europe, 2011; Subata E., Gilman M., Alho H., Maremmani I. “Recommendations for measuring treatment outcomes in opioid dependence management: consensus from the GLADD mission”, *Heroin Addiction and Related Clinical Problems*, 2013, Vol. 15, 3 55-60; Raben D., Jakobsen F.S., Nakagawa F., Moller N.F., Lundgren J., Subata E., “HIV/AIDS Treatment and Care in Estonia: Evaluation Report”, June 2014, WHO Regional Office for Europe.

Selected meetings attended

Training of 30 Latvian specialists on Clinical and Social Aspects of Pharmacotherapy of Opioid Dependence with Methadone (UNODC Treatnet modules used), January 2010, Riga, Latvia, UNODC Regional Project for the Baltic States (Lead Trainer); Training of 60 Belarus specialists on Clinical and Social Aspects of Pharmacotherapy of Opioid Dependence with Methadone (Eurasian Harm Reduction Network (EHRN) Knowledge Hub modules used), May 2010, Minsk, Belarus, UNDP Office for Belarus, EHRN (Lead Trainer); Study visit on practical opioid dependence treatment and HIV/TB management knowledge for officials from the Ukrainian Ministry of Health and chief doctors of Ukrainian healthcare institutions, September 2010, EHRN, United States Agency for International Development, Regional Mission for Ukraine, Belarus and Moldova, International HIV/AIDS Alliance in Ukraine (Lead Trainer); Evaluation of methadone maintenance programme in Estonian penitentiary institutions, November 2010, Tallinn, Estonia, UNODC Regional Project for the Baltic States; Adaptation

of Addiction Severity Index, UNODC Treatnet, 5th edition, 3.0 version into Lithuanian language and treatment planning software development, training of 42 Lithuanian professionals and introduction into clinical practice, January 2010-January 2011, Vilnius, Lithuania, UNODC Regional Project for the Baltic States (Team leader and head trainer); Implementation of the evaluation of a pilot opioid substitution therapy programme in prisons in Kyrgyzstan; report published, January 2010-May 2011, Vilnius, WHO Regional Office for Europe (Investigator); Preparation of the draft report on “Evaluation of substitution treatment in prisons” on pilot opioid substitution treatment in Kyrgyz prisons (2009-2010), May 2011, Bishkek, Kyrgyzstan, WHO Regional Office for Europe; Organization of the study visit for members of the Belarus National Assembly and high rank law enforcement officers on treatment as alternative to prison sentences for drug offences, 1 October 2011, ongoing, Pavlodar, Kazakhstan, Vilnius, ICAP, Columbia University, Mailman School of Public Health; Evaluation of Medication Assisted Treatment (MAT) of opioid dependence in Kazakhstan, Kyrgyzstan and Tajikistan (2012), Vilnius WHO Regional Office for Europe; Organization of WHO Office for Europe meeting on how to scale-up and implement opioid substitution therapy (OST) in selected EU countries; development of regional level Guidance on the scaling-up and implementation of OST (in progress), 2012, Tashkent, Uzbekistan, UNDP Office for Uzbekistan; Assessment of the situation on the opioid dependence treatment aiming at improving of HIV prevention and control among injecting drug users in Uzbekistan, the assessment report for country UNDP office; August 2012, Vilnius, UNDP Office for Belarus; Organization of the study visit for members of Belarus dependence specialists in Vilnius centre of Addictive Disorders, August 2012, Vilnius, Chisinau, PAS Centre, UNODC Moldova; Evaluation of Opioid Substitution Therapy in Moldova, September 2013, Vilnius, WHO Collaborating Centre for Harm Reduction at Vilnius University; Training of six professionals from Tajikistan, “Improving quality of quality of pharmacotherapy of opioid dependence and prevention of HIV: an integrated approach, September 2013, Dushanbe, Tajikistan, WHO Regional Office for Europe; Midterm review of the national AIDS programme in Tajikistan; the IDU component, November 2013, Kiev, Donetsk, Simferopol, Yalta, Ivano-Frankivsk International Charitable Foundation, HIV/AIDS Alliance in Ukraine; Evaluation of substitution maintenance programme in Ukraine, March 2014, Minsk, Belarus, UNAIDS Belarus; Contribution through presentation and discussion to the development of opioid substitution therapy in Belarus, May 2014, Tallinn, Narva, Kohla-Jarve, Estonia, WHO Regional Office for Europe; Evaluation of HIV/AIDS treatment and care in Estonia, July 2014, Tashkent, Uzbekistan, UNODC, Regional Office for Central Asia; Educational training workshop “Improvement of the Adherence to ARV therapy among people who inject drugs in Uzbekistan”.